Atara Biotherapeutics Inc (ATRA)

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational ProgressMay 12, 2026 4:05 PM
Business Wire Productive meeting held with the FDA; planning for tabelecleucel BLA resubmission Operating efficiencies and ATM proceeds extend cash runway into mid-2027 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2026 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD) As previously communicated, Pierre Fabre Pharmaceuticals (PFP), with Atara’s support, had a productive meeting with the FDA and discussed a potential path forward to resubmitting the tab-cel Biologics License Application (BLA). The FDA agreed that a single arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well controlled study and provide safety and efficacy data in support of a marketing application of tab-cel for the proposed indication. PFP has indicated they intend to submit an updated dataset with additional patients and longer follow-up from the pivotal Phase 3 single arm ALLELE study as well as supportive data, as a part of the resubmission plan being defined with the FDA. Atara anticipates providing a further regulatory update in the third quarter. First Quarter 2026 Financial Results Cash, cash equivalents and short-term investments as of March 31, 2026 totaled $8.4 million, as compared to $8.5 million as of December 31, 2025. Net cash used in operating activities was $3.1 million for the first quarter 2026, as compared to $28.1 million in the same period in 2025. Total revenues were $0.5 million for the first quarter 2026, as compared to $98.1 million for the same period in 2025. The prior-year period reflects a one-time acceleration of revenue recognized upon the transfer of tab-cel manufacturing responsibilities to Pierre Fabre Laboratories on March 31, 2025. In the current period, commercialization revenue relates solely to ongoing regulatory activities Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $0.8 million for the first quarter 2026, as compared to $6.0 million for the same period in 2025. Research and development expenses were $0.2 million for the first quarter 2026, as compared to $27.4 million for the same period in 2025. Research and development expenses also include $0.3 million of non-cash stock-based compensation expenses for the first quarter 2026, as compared to $1.6 million for the same period in 2025. General and administrative expenses were $3.6 million for the first quarter 2026, as compared to $11.5 million for the same period in 2025. General and administrative expenses include $0.5 million of non-cash stock-based compensation expenses for the first quarter 2026, as compared to $2.6 million for the same period in 2025. Atara reported a net loss of $4.1 million, or ($0.29) basic and diluted loss per share, for the first quarter 2026, as compared to net income of $38.0 million, or $3.53 basic earnings per share and $3.50 diluted earnings per share, for the same period in 2025. 2026 Outlook and Cash Runway: Operating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025. Atara expects its cash, cash equivalents, and short-term investments as of March 31, 2026, combined with $4.8 million of ATM proceeds after quarter end and operating efficiencies achieved in 2025, will be sufficient to fund planned operations into mid-2027. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn. Forward-Looking Statements This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the timing of PFP’s resubmission, the potential characteristics and benefits of tab-cel, and the results of, and prospects for bringing tab-cel to U.S. patients with EBV+ PTLD, the global partnership with Pierre Fabre Medicament involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Medicament, including the receipt, timing and amount of any payments to be received by Atara thereunder; and (2) Atara’s cash runway, receipt of potential milestone payments, and estimated reduction in operating expenses, including Atara’s ability to fund its planned operations into mid-2027. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of tab-cel, including the risk that a resubmission of the tab-cel BLA may not address the deficiencies identified in the Complete Response Letter received on January 9, 2026 or other issues that may be raised by the FDA on review; the fact that PFP, and not Atara, holds the tab-cel BLA and controls the timing, content and strategy of any resubmission and related FDA interactions, and Atara's ability to influence the resubmission process is limited; our ability to access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Atara’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. Financials ATARA BIOTHERAPEUTICS, INC. Condensed Consolidated Balance Sheets (Unaudited) (In thousands)       March 31,   December 31,     2026     2025   Assets         Current assets:         Cash and cash equivalents   $ 8,360     $ 8,482   Accounts receivable     —       1,253   Other current assets     3,813       2,477   Total current assets     12,173       12,212   Property and equipment, net     55       73   Operating lease assets     6,879       7,064   Other assets     890       886   Total assets   $ 19,997     $ 20,235             Liabilities and stockholders’ equity (deficit)         Current liabilities:         Accounts payable   $ 637     $ 127   Accrued compensation     629       1,271   Accrued research and development expenses     41       82   Deferred revenue     684       716   Liability related to the sale of future revenues – current portion     715       9,750   Other current liabilities     2,939       2,976   Total current liabilities     5,645       14,922   Operating lease liabilities – long-term     9,076       9,347   Liability related to the sale of future revenues – long-term     40,759       32,673   Other long-term liabilities     1,829       1,795   Total liabilities     57,309       58,737             Commitments and contingencies (Note 9)                   Stockholders’ equity (deficit):         Common stock—$0.0001 par value, 500,000 shares authorized as of March 31, 2026 and December 31, 2025; 8,512 and 7,324 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively     1       1   Additional paid-in capital     1,988,697       1,983,361   Accumulated other comprehensive income (loss)     —       1   Accumulated deficit     (2,026,010 )     (2,021,865 ) Total stockholders’ equity (deficit)     (37,312 )     (38,502 ) Total liabilities and stockholders’ equity (deficit)   $ 19,997     $ 20,235   ATARA BIOTHERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts)       Three Months Ended March 31,     2026     2025   Commercialization revenue   $ 516     $ 98,149   Costs and operating expenses:         Cost of commercialization revenue     124       20,439   Research and development expenses     164       27,433   General and administrative expenses     3,597       11,475   Total costs and operating expenses     3,885       59,347   Income (loss) from operations     (3,369 )     38,802   Other income (expense), net:         Interest income     54       236   Interest expense     (830 )     (1,017 ) Other income (expense), net     —       (11 ) Total other income (expense), net     (776 )     (792 ) Income (loss) before provision for (benefit from) income taxes     (4,145 )     38,010   Provision for (benefit from) income taxes     —       —   Net income (loss)   $ (4,145 )   $ 38,010   Other comprehensive gain (loss):         Unrealized gain (loss) on available-for-sale securities     (1 )     (8 ) Comprehensive income (loss)   $ (4,146 )   $ 38,002             Basic (loss) earnings per common share   $ (0.29 )   $ 3.53   Diluted (loss) earnings per common share   $ (0.29 )   $ 3.50             Basic and diluted weighted-average shares outstanding     14,081       10,764   Diluted weighted-average shares outstanding     14,081       10,851     View source version on businesswire.com: https://www.businesswire.com/news/home/20260512257848/en/ Investor and Media Relations
Amber Daugherty
Sr. Director, Strategy and Operations
adaugherty@atarabio.com Original: Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

ATRA...............................p/m

FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline AliveMay 7, 2026 11:03 AM
IH Market News Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor Takeaways Atara Biotherapeutics (NASDAQ:ATRA) said the FDA discussed a potential resubmission path for tabelecleucel following a Type A meeting. The regulatory update centers on tab-cel’s Biologics License Application after the FDA previously issued a Complete Response Letter. Pierre Fabre plans to submit updated data from the Phase 3 ALLELE study, including additional patients and longer follow-up. The FDA indicated a single-arm study with an appropriate historical control could support a future marketing application. Investors may view the update as reducing some regulatory uncertainty around tab-cel’s approval pathway. Why ATRA Stock Is in Focus Atara Biotherapeutics (NASDAQ:ATRA) provided a regulatory update tied to tabelecleucel, or tab-cel, after partner Pierre Fabre Pharmaceuticals met with the FDA to discuss the Complete Response Letter issued for the therapy’s Biologics License Application.According to the company, the FDA agreed that a single-arm study using an appropriate historical control could potentially serve as an adequate and well-controlled study to support a future marketing application for tab-cel.Pierre Fabre intends to include updated data from the pivotal Phase 3 ALLELE study in a resubmission package. The planned update would include additional patients and longer follow-up data involving adults and children with relapsed or refractory EBV-positive post-transplant lymphoproliferative disease following solid organ or hematopoietic cell transplant.“We are grateful to the agency for engaging in a collaborative conversation with our partners, Pierre Fabre, and us. We appreciate the FDA’s continued engagement with PFP and Atara, and we believe the Type A Meeting provided helpful alignment on the regulatory framework to resubmit,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “We will continue to support Pierre Fabre as it prepares the resubmission and anticipate providing a further regulatory update in the third quarter.” Why This Matters for Investors The update may matter to investors because it suggests the FDA remains open to a potential approval pathway for tab-cel despite the earlier Complete Response Letter.Regulatory setbacks can create major uncertainty for biotechnology companies, particularly for therapies targeting niche patient populations. The FDA’s willingness to discuss a framework involving updated Phase 3 data and historical controls may help stabilize sentiment around the program.The company’s comments also suggest the resubmission process is advancing rather than restarting entirely with a new large-scale trial requirement. That distinction could affect investor expectations around timing, development costs, and commercialization prospects.At the same time, regulatory risk remains significant. The FDA did not approve the application, and the eventual outcome will depend on the strength of the updated dataset and whether the agency determines the evidence sufficiently supports safety and efficacy. What to Watch Next Investors will likely watch for the regulatory update Atara expects to provide in the third quarter.Additional focus may center on the timing of the tab-cel resubmission, the scope of the updated ALLELE study data, and any further FDA feedback as the process moves forward.Atara Biotherapeutics stock price Original: FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive

ATRA....................https://stockcharts.com/sc3/ui/?s=ATRA&p=W&b=5&g=0&id=p86431144783

Atara Biotherapeutics Provides Regulatory Update on TabelecleucelMay 7, 2026 8:05 AM
Business Wire Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update following the recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) to the Biologics License Application (BLA) for tabelecleucel (tab-cel) held by our partner Pierre Fabre Pharmaceuticals, Inc. (PFP). PFP, with Atara’s support, had a productive meeting with the FDA and discussed a potential path forward to resubmitting the tab-cel BLA. The FDA agreed that a single arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well controlled study and provide safety and efficacy data in support of a future marketing application of tab-cel for the proposed indication. PFP has indicated they intend to submit an updated dataset with additional patients and longer follow up from the pivotal Phase 3 single arm ALLELE study of tabelecleucel in adults and children two years of age and older with R/R EBV+ PTLD following solid organ transplant or hematopoietic cell transplant as well as supportive data, as a part of the resubmission plan being defined with the FDA. “We are grateful to the agency for engaging in a collaborative conversation with our partners, Pierre Fabre, and us. We appreciate the FDA’s continued engagement with PFP and Atara, and we believe the Type A Meeting provided helpful alignment on the regulatory framework to resubmit,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “We will continue to support Pierre Fabre as it prepares the resubmission and anticipate providing a further regulatory update in the third quarter.” About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn. Forward-Looking Statements This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the timing of PFP’s resubmission of the tab-cel BLA, the potential characteristics and benefits of tab-cel; and (2) the prospect of bringing tab-cel to U.S. patients with EBV+ PTLD. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of tab-cel, including the risk that a resubmission of the tab-cel BLA may not address the deficiencies identified in the CRL or other issues that may be raised by the FDA on review; the fact that PFP, and not Atara, holds the tab-cel BLA and controls the timing, content and strategy of any resubmission and related FDA interactions, and Atara's ability to influence the resubmission process is limited; our ability to access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Atara’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507608246/en/ Investor and Media Relations
Amber Daugherty
Sr. Director, Strategy and Operations
adaugherty@atarabio.com Original: Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRAMarch 26, 2026 7:30 AM
Business Wire
The DJS Law Group reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.


Shareholders who purchased shares of ATRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.


CLASS PERIOD: May 20, 2024 to January 9, 2026


DEADLINE: May 22, 2026


CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Atara’s deficient ALLELE study and manufacturing problems made it unlikely the FDA would approve its BLA for tabelecleucel. The Company overstated the regulatory prospects of tabelecleucel. Based on these facts, Atara’s public statements were false and materially misleading throughout the class period.


If you are a shareholder who suffered a loss, contact us to participate.


WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.


Join the case to recover your losses.


This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326324232/en/
David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com


Original: Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRA

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational ProgressMarch 16, 2026 4:05 PM
Business Wire
Atara delivers significant operational efficiencies and extends cash runway through year-end 2026


A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA


Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates.


“We continue to focus on streamlining our costs and liabilities, allowing us to be a nimbler, fit for purpose organization,” said Cokey Nguyen Ph.D., President and Chief Executive Officer of Atara. “With the adjustments we have made we are able to focus on supporting our partner, Pierre Fabre Pharmaceuticals, as they work towards addressing the concerns in the latest Complete Response Letter with the agency. We strongly believe that tabelecleucel can bring substantial benefit to post-transplant lymphoproliferative disease patients and we are committed to supporting Pierre Fabre Pharmaceuticals as they get this life-saving drug to the finish line in the U.S.”


Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD)


A Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled for our partner Pierre Fabre Pharmaceuticals to discuss the issues raised by the FDA in the Complete Response Letter received in January 2026. We anticipate providing a regulatory update in the second quarter.


Corporate Updates


As previously communicated, Atara entered into an amendment (Amendment) to the Purchase and Sale Agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty (“HCRx”). Under the terms of the Amendment, HCRx agreed to amend the due date of the one-time $9.0 million cash payment associated with the achievement of a certain milestone from June 30, 2026 to January 1, 2028 in exchange for the issuance of a warrant to purchase up to 400,000 shares of Atara common stock.


Financial Update:


Fourth Quarter and Full Year 2025 Financial Results:



Cash, cash equivalents and short-term investments as of December 31, 2025 totaled $8.5 million, as compared to $42.5 million as of December 31, 2024.



Net cash used in operating activities was $5.7 million and $50.9 million for the fourth quarter and fiscal year 2025, as compared to $24.5 million and $68.7 million for the same periods in 2024.



Atara reported a net loss of ($3.4) million, or ($0.25) per share, and a net income of $32.7 million, or $2.61 per share, for the fourth quarter and fiscal year 2025, respectively, as compared to a net loss of ($12.7) million, or ($1.19) per share, and ($85.4) million, or ($11.41) per share, for the same periods in 2024.



Commercialization revenues were $120.8 million in 2025 as compared to $128.9 million in 2024.



Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $1.6 million and $11.9 million for the fourth quarter and fiscal year 2025, respectively, as compared to $6.9 million and $32.1 million for the same periods in 2024.



Research and development expenses were ($0.2) million and $37.4 million for the fourth quarter and fiscal year 2025, respectively, compared to $28.7 million and $151.5 million for the same periods in 2024. The 2025 results include a $2.6 million non-cash gain from an ARC facility lease amendment, resulting in a fourth-quarter credit rather than an expense.



Research and development expenses include $0.4 million and $2.9 million of non-cash stock-based compensation expenses for the fourth quarter and fiscal year 2025, respectively, compared to $2.6 million and $13.5 million for the same periods in 2024.



General and administrative expenses were $4.3 million and $26.3 million for the fourth quarter and fiscal year 2025, respectively, as compared to $9.4 million and $39.9 million for the same periods in 2024.



General and administrative expenses include $1.1 million and $6.9 million of non-cash stock-based compensation expenses for the fourth quarter and fiscal year 2025, respectively, compared to $3.3 million and $13.5 million for the same periods in 2024.



2026 Outlook and Cash Runway:



Operating expenses are expected to continue to decline significantly year-over-year as a result of the comprehensive cost-reduction initiatives completed in 2025.



Atara expects that cash, cash equivalents and short-term investments as of December 31, 2025, combined with recent ATM proceeds of $3.0 million and the operating efficiencies realized in 2025, will be sufficient to fund planned operations through year-end 2026.



About Atara Biotherapeutics, Inc.


Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.


Forward-Looking Statements


This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the timing and results of the Type A meeting and the potential path forward for the timely accelerated approval of EBVALLO™, the potential characteristics and benefits of tab-cel, and the results of, and prospects for bringing tab-cel to U.S. patients with EBV+ PTLD, the global partnership with Pierre Fabre Medicament involving tab-cel, and the potential financial benefits to Atara as a result of the global partnership with Pierre Fabre Medicament, including the receipt, timing and amount of any payments to be received by Atara thereunder; (2) the timing of the $9.0 million cash payment to HCRx; (3) Atara’s cash runway, receipt of potential milestone payments, and estimated reduction in operating expenses, including Atara’s ability to fund its planned operations to year-end 2026; and (4) Atara’s evaluation of strategic alternatives and ability to consummate one or more strategic transactions. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of the resubmitted BLA for tab-cel; our ability to access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; the timing of the strategic review process; whether Atara will pursue any strategic alternatives; in the event Atara pursues a strategic alternative, that the strategic alternative may not be attractive or ultimately consummated; whether any strategic alternative will result in additional value for Atara and its stockholders; whether the process will have an adverse impact on Atara and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.


Financials




ATARA BIOTHERAPEUTICS, INC.




Consolidated Balance Sheets




(In thousands, except per share amounts)











 



 






 






December 31,






 






December 31,








 






 






2025






 






2024








Assets






 






 






 






 








Current assets:






 






 






 






 








Cash and cash equivalents






 






$






8,482






 






 






$






25,030






 








Short-term investments






 






 






—






 






 






 






17,466






 








Restricted cash






 






 






—






 






 






 






146






 








Accounts receivable






 






 






1,253






 






 






 






1,482






 








Inventories






 






 






—






 






 






 






10,655






 








Other current assets






 






 






2,477






 






 






 






10,115






 








Total current assets






 






 






12,212






 






 






 






64,894






 








Property and equipment, net






 






 






73






 






 






 






1,294






 








Operating lease assets






 






 






7,064






 






 






 






39,807






 








Other assets






 






 






886






 






 






 






3,103






 








Total assets






 






$






20,235






 






 






$






109,098






 








 






 






 






 






 








Liabilities and stockholders’ equity (deficit)






 






 






 






 








Current liabilities:






 






 






 






 








Accounts payable






 






$






127






 






 






$






4,367






 








Accrued compensation






 






 






1,271






 






 






 






6,589






 








Accrued research and development expenses






 






 






82






 






 






 






7,984






 








Deferred revenue






 






 






716






 






 






 






95,092






 








Liability related to the sale of future revenues – current portion






 






 






9,750






 






 






 






382






 








Other current liabilities






 






 






2,976






 






 






 






20,160






 








Total current liabilities






 






 






14,922






 






 






 






134,574






 








Operating lease liabilities – long-term






 






 






9,347






 






 






 






29,914






 








Liability related to the sale of future revenues – long-term






 






 






32,673






 






 






 






38,624






 








Other long-term liabilities






 






 






1,795






 






 






 






3,269






 








Total liabilities






 






 






58,737






 






 






 






206,381






 








 






 






 






 






 








Commitments and contingencies (Note 9)






 






 






 






 








 






 






 






 






 








Stockholders’ equity (deficit):






 






 






 






 








Common stock—$0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024, respectively; 7,324 and 5,859 shares issued and outstanding as of December 31, 2025 and 2024, respectively






 






 






1






 






 






 






1






 








Additional paid-in capital






 






 






1,983,361






 






 






 






1,957,261






 








Accumulated other comprehensive income






 






 






1






 






 






 






8






 








Accumulated deficit






 






 






(2,021,865






)






 






 






(2,054,553






)








Total stockholders’ equity (deficit)






 






 






(38,502






)






 






 






(97,283






)








Total liabilities and stockholders’ equity (deficit)






 






$






20,235






 






 






$






109,098






 









ATARA BIOTHERAPEUTICS, INC.




Consolidated Statements of Operations and Comprehensive Income (Loss)




(In thousands, except per share amounts)









 



 






 






Years Ended December 31,








 






 






2025






 






2024








Commercialization revenue






 






$






120,772






 






 






$






128,940






 








Total revenue






 






 






120,772






 






 






 






128,940






 








Costs and operating expenses:






 






 






 






 








Cost of commercialization revenue






 






 






21,212






 






 






 






21,009






 








Research and development expenses






 






 






37,445






 






 






 






151,483






 








General and administrative expenses






 






 






26,253






 






 






 






39,886






 








Total costs and operating expenses






 






 






84,910






 






 






 






212,378






 








Income (loss) from operations






 






 






35,862






 






 






 






(83,438






)








Other income (expense), net:






 






 






 






 








Interest income






 






 






683






 






 






 






2,110






 








Interest expense






 






 






(3,792






)






 






 






(4,615






)








Other income (expense), net:






 






 






(34






)






 






 






528






 








Total other income (expense), net






 






 






(3,143






)






 






 






(1,977






)








Income (loss) before provision for (benefit from) income taxes






 






 






32,719






 






 






 






(85,415






)








Provision for (benefit from) income taxes






 






 






31






 






 






 






(12






)








Net income (loss)






 






$






32,688






 






 






$






(85,403






)








Other comprehensive gain (loss):






 






 






 






 








Unrealized gain (loss) on available-for-sale securities






 






 






(7






)






 






 






212






 








Comprehensive income (loss)






 






$






32,681






 






 






$






(85,191






)








 






 






 






 






 








Basis earnings (loss) per common share






 






$






2.61






 






 






$






(11.41






)








Diluted earnings (loss) per common share






 






$






2.57






 






 






$






(11.41






)








 






 






 






 






 








Basic weighted-average shares outstanding






 






 






12,544






 






 






 






7,488






 








Diluted weighted-average shares outstanding






 






 






12,718






 






 






 






7,488






 







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260316154875/en/
Investor and Media Relations

Amber Daugherty

Sr. Director, Strategy and Operations

adaugherty@atarabio.com


Original: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara Biotherapeutics Provides Regulatory Update on TabelecleucelMarch 12, 2026 8:05 AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) to the Biologics License Application (BLA) for tabelecleucel (tab-cel) held by our partner Pierre Fabre Pharmaceuticals.


Pierre Fabre Pharmaceuticals, with Atara’s support, will meet with the agency to collaboratively address the points from the CRL and enable a resubmission with the additional efficacy data that has been collected since the original BLA submission.


“We are pleased that the FDA has granted a Type A Meeting to our partner, Pierre Fabre, and hope to gain clarity on a path forward for re-submission of the tab-cel BLA,” said Cokey Nguyen, President and Chief Executive Officer of Atara. “We anticipate providing a regulatory update in the second quarter.”


About Atara Biotherapeutics, Inc.


Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.


Forward-Looking Statements


This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel, including the timing of the Type A meeting and PFP’s and Atara’s plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of EBVALLO™, the potential characteristics and benefits of tab-cel; and (2) the prospect of bringing tab-cel to U.S. patients with EBV+ PTLD. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of tab-cel; our ability to access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; risks and uncertainties related to Atara’s financial close and year-end audit procedures; the timing of the strategic review process; whether Atara will pursue any strategic alternatives; in the event Atara pursues a strategic alternative, that the strategic alternative may not be attractive or ultimately consummated; whether any strategic alternative will result in additional value for Atara and its stockholders; whether the process will have an adverse impact on Atara and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Atara’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260312166607/en/
Investor and Media Relations

Amber Daugherty

Sr. Director, Strategy and Operations

adaugherty@atarabio.com


Original: Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

ATRA........................................................https://stockcharts.com/sc3/ui/?s=ATRA&p=W&b=5&g=0&id=p86431144783

$30++++ fda decision on the 15th

$30++++ fda decision on the 15th

...

ATRA under $13

ATRA under $10

ATRA under $10

Taking another ride here.

Broke $1M traded again.....finally.

ATRA: THANKS to BOTH of you Fellows for the EARLY heads-up!!!

7.77m VOL NICE, I LIKE TPET FOR A 4AM GAPPER


T31M OS TRADED 2X ALREADY

FLOAT ROTATION 3X


LOOKING FOR .40-50

ATRA looks good

Having a good day despite the offering currently up 20%

https://ih.advfn.com/stock-market/NASDAQ/atara-biotherapeutics-ATRA/stock-news/92982254/atara-biotherapeutics-announces-15-million-regist

Although I'm gonna say no. However, in this cockeyed market, we don't know. We are dealing with a different universe brother. Very strange

hmmmmm .70 wonder if this will continue tomorrow


os and float same 95M

https://finviz.com/quote.ashx?t=ATRA&ty=c&ta=1&p=d

NEWS
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). Building on the earlier partnership announced in October 2021 to commercialize tab-cel in Europe, this transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets.

“We are pleased to announce the closing of the transaction with Pierre Fabre Laboratories who are committed to expanding the reach of tab-cel to patients in the U.S. and across the globe,” said Pascal Touchon, President and Chief Executive Officer of Atara. “Atara’s priority is to now submit the tab-cel BLA filing package, while initiating our first clinical study with ATA3219, a potential best-in-class allogeneic off-the-shelf CD19 CAR T with unique features.”

With the closing of the transaction, Atara will receive approximately USD 27 million in cash upfront and initial inventory purchase. Under the agreement, Atara has the potential to receive up to a total of USD 640 million and significant double-digit tiered royalties on net sales, including up to USD 100 million in potential regulatory milestones through BLA approval. In addition, Pierre Fabre Laboratories will reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer, and purchase future tab-cel inventory through the manufacturing transfer date.

Substantially all tab-cel manufacturing, clinical, and regulatory activities are planned to transition from Atara to Pierre Fabre Laboratories at the time of BLA transfer.

Atara plans to submit the BLA to the U.S. Food and Drug Administration (FDA) for tab-cel for the treatment of post-transplant lymphoproliferative disease (PTLD) in the second quarter of 2024.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X (formerly known as Twitter) and LinkedIn.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing and progress of tab-cel®, including a potential BLA, the potential characteristics and benefits of tab-cel®, and the progress and results of, prospects for, and closing of the expanded global partnership with Pierre Fabre Laboratories involving tab-cel®, and the potential financial benefits to Atara as a result of the expanded global partnership with Pierre Fabre Laboratories; (2) the development, t

ATRA under $2

Can be squeezing too hard with a 17% drop in price. ??????

E. F. Hutton analyst maintains a BUY with a $25 target!!!! Why did ATRA do so badly today with a 17% decline??? Any thoughts. I am holding but...........

Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by JPMorgan Chase & Co. to Overweight

Posted by ABMN Staff on May 19th, 2021

Atara Biotherapeutics logoAtara Biotherapeutics (NASDAQ:ATRA) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a $29.00 price objective on the biotechnology company’s stock, up from their prior price objective of $23.00. JPMorgan Chase & Co.‘s target price points to a potential upside of 99.59% from the company’s previous close.

Several other research firms have also issued reports on ATRA. HC Wainwright reduced their price target on shares of Atara Biotherapeutics from $32.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, May 11th. Citigroup raised Atara Biotherapeutics from a “neutral” rating to a “buy” rating and set a $27.00 target price on the stock in a report on Tuesday, March 2nd. Finally, William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a report on Tuesday, March 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $34.33.

Shares of NASDAQ ATRA opened at $14.53 on Wednesday. The business has a fifty day moving average price of $14.06 and a two-hundred day moving average price of $17.83. The stock has a market capitalization of $1.22 billion, a PE ratio of -3.15 and a beta of 2.65. Atara Biotherapeutics has a fifty-two week low of $8.90 and a fifty-two week high of $28.20.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, May 3rd. The biotechnology company reported ($0.86) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.06. As a group, equities research analysts expect that Atara Biotherapeutics will post -3.89 earnings per share for the current fiscal year.
In other Atara Biotherapeutics news, CFO Utpal Koppikar sold 1,761 shares of the business’s stock in a transaction that occurred on Friday, March 26th. The shares were sold at an average price of $14.58, for a total transaction of $25,675.38. Following the sale, the chief financial officer now directly owns 172,582 shares of the company’s stock, valued at approximately $2,516,245.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joe Newell sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 15th. The shares were sold at an average price of $17.41, for a total transaction of $121,870.00. Following the completion of the transaction, the chief operating officer now owns 145,219 shares of the company’s stock, valued at $2,528,262.79. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,901 shares of company stock worth $238,537. 4.30% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the stock. Signaturefd LLC raised its position in Atara Biotherapeutics by 6,757.1% during the 1st quarter. Signaturefd LLC now owns 2,400 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,365 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Atara Biotherapeutics by 181.5% during the fourth quarter. Penserra Capital Management LLC now owns 1,785 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,151 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Atara Biotherapeutics by 50.9% in the first quarter. Pacer Advisors Inc. now owns 4,608 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 1,554 shares during the period. Nisa Investment Advisors LLC increased its position in Atara Biotherapeutics by 589.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,620 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 3,950 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in Atara Biotherapeutics in the first quarter valued at $118,000.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Breaking News: $ATRA Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara’s allogeneic CAR T therapy leverages the combination of cell intrinsic PD1DNR checkpoint inhibition and 1XX CAR signaling technologies built on the Company’s novel EBV T-cell platform Preclinical findings demonstrate potent antitumor activity, persistence a...

In case you are interested ATRA - Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

$ATRA bears are running Atara Biotherapeutics Inc Nasdaq Atra Short Squeeze

News: $ATRA Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference call and webcast today at 3:30 p.m. CEST / 9:30 a.m. EDT ...

In case you are interested ATRA - Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

News: $ATRA Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was well-tolerated and showed encouraging anti-tumor activity in combination with pembrolizumab, a PD-1 checkpoint inhibitor  Best overall r...

Read the whole news https://marketwirenews.com/news-releases/atara-biotherapeutics-announces-collaborator-presentation-of-positive-phase-1-clinical-results-for-a-mesothelin-targeted-car-t-immunotherapy-in-patients-with-advanced-mesothelioma-7919490.html

Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclero DJNF
Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to proceed with patient enrollment at U.S. sites for its ongoing global Phase 1 clinical study to evaluate ATA188 in patients with progressive or relapsing-remitting multiple sclerosis (MS). ATA188, the Company's off-the-shelf T-cell immunotherapy using a complementary targeted antigen recognition technology licensed from QIMR Berghofer Medical Research Institute, selectively targets specific Epstein-Barr virus (EBV) antigens believed to play an important role in the pathogenesis of MS. Atara initiated the open-label, single arm Phase 1 study in MS patients in the fourth quarter of 2017 in Australia.

"We are pleased with FDA's decision to allow off-the-shelf ATA188 to proceed into clinical development in patients with MS in the U.S.," said Chris Haqq M.D., Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Atara Biotherapeutics. "We believe that an off-the-shelf T-cell immunotherapy such as ATA188 may allow for a more consistent reactivity against target EBV antigens, which may be correlated with clinical improvements based on data from a previous autologous ATA190 Phase 1 study in patients with progressive MS. We look forward to the first results from the ATA188 Phase 1 study in patients with progressive MS in the first half of

BRIDGER MANAGEMENT, LLC has filed a new 13G, reporting 5.2% ownership in $ATRA - https://fintel.io/so/us/atra

ATRA bullish 21.12

Need this to drop 10%

All sellers no buyers... Down she goes

I've been shorting this the past few days, easy money

Atara’s Discontinuation Paints it as a Potential Short

http://marketexclusive.com/ataras-discontinuation-paints-it-as-a-potential-short/1173/

Keep on falling

Down she goes......

I see the uptrend. Stock is breaking the resistance line and the downward trendline!

could double from here

$ATRA recent news/filings

bullish
symmetrical triangle breakout soon

## source: finance.yahoo.com

Fri, 10 Jul 2015 05:11:00 GMT ~ 1:11 am Atara Biotherapeutics prices offering of 3,461,538 shares of its common stock at $52.00 per share


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#atra
*********************************************************

Fri, 10 Jul 2015 00:31:02 GMT ~ Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock

[at noodls] - SOUTH SAN FRANCISCO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating ...

read full: http://www.noodls.com/view/C39E7CB948A50C763B65D33B826D5A82DC6BDA32
*********************************************************

Fri, 10 Jul 2015 00:08:28 GMT ~ Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Atara Biotherapeutics, Inc. , a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the pricing ...

read full: http://finance.yahoo.com/news/atara-bio-announces-pricing-180-000828259.html
*********************************************************

Tue, 07 Jul 2015 20:47:09 GMT ~ Atara Bio Announces Proposed Offering of Common Stock

[at noodls] - SOUTH SAN FRANCISCO, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating ...

read full: http://www.noodls.com/view/D36C89829CB05A1A21C48C50D9F60376308A5299
*********************************************************

Tue, 07 Jul 2015 20:05:00 GMT ~ Atara Bio Announces Proposed Offering of Common Stock

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Atara Biotherapeutics, Inc. , a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it ...

read full: http://finance.yahoo.com/news/atara-bio-announces-proposed-offering-200500993.html
*********************************************************

$ATRA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ATRA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ATRA/company-info
Ticker: $ATRA
OTC Market Place: Not Available
CIK code: not found
Company name: Atara Biotherapeutics, Inc.
Incorporated In:

$ATRA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ATRA extra dd links

Company name: Atara Biotherapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ATRA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ATRA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ATRA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/news - http://finance.yahoo.com/q/h?s=ATRA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ATRA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ATRA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ATRA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Atara+Biotherapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Atara+Biotherapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Atara+Biotherapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ATRA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ATRA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ATRA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ATRA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ATRA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ATRA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ATRA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ATRA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ATRA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ATRA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ATRA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ATRA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ATRA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ATRA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ATRA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ATRA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ATRA



$ATRA DD Notes ~ http://www.ddnotesmaker.com/ATRA

On watch......

$ATRA recent news/filings

bullish
bullish engulfing

## source: finance.yahoo.com

Wed, 29 Apr 2015 22:15:16 GMT ~ Nasdaq stocks posting largest percentage decreases

[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220242625--finance.html
*********************************************************

Tue, 28 Apr 2015 12:38:12 GMT ~ Atara Biotherapeutics (ATRA) Falls: Stock Goes Down 19.4% - Tale of the Tape


read full: http://finance.yahoo.com/news/atara-biotherapeutics-atra-falls-stock-123812970.html
*********************************************************

Mon, 20 Apr 2015 10:46:49 GMT ~ EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

[at noodls] - SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center ...

read full: http://www.noodls.com/view/F5E86C4ED97E6021996505EB6A500C5F8341F79F
*********************************************************

Mon, 20 Apr 2015 10:30:00 GMT ~ EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif. -- Atara Biotherapeutics, Inc. today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic ...

read full: http://finance.yahoo.com/news/ebv-ctl-clinical-trial-data-103000068.html
*********************************************************

Sun, 19 Apr 2015 12:55:12 GMT ~ Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available

[at noodls] - SOUTH SAN FRANCISCO, Calif., April 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus ...

read full: http://www.noodls.com/view/CFC4866E6F03B003009024E6E4A9953CC6962A7A
*********************************************************

$ATRA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ATRA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ATRA/company-info
Ticker: $ATRA
OTC Market Place: Not Available
CIK code: not found
Company name: Atara Biotherapeutics, Inc.
Incorporated In:

$ATRA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$ATRA extra dd links

Company name: Atara Biotherapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ATRA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ATRA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ATRA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/news - http://finance.yahoo.com/q/h?s=ATRA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ATRA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ATRA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ATRA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Atara+Biotherapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Atara+Biotherapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Atara+Biotherapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ATRA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ATRA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ATRA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ATRA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ATRA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ATRA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ATRA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ATRA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ATRA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ATRA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ATRA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ATRA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ATRA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ATRA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ATRA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ATRA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ATRA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ATRA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ATRA



$ATRA DD Notes ~ http://www.ddnotesmaker.com/ATRA